PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 96 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $576,000 | +38.5% | 68,236 | +123.1% | 0.02% | +64.3% |
Q1 2022 | $416,000 | -4.8% | 30,590 | +37.8% | 0.01% | +7.7% |
Q4 2021 | $437,000 | -39.7% | 22,194 | -1.7% | 0.01% | -43.5% |
Q3 2021 | $725,000 | -5.2% | 22,589 | 0.0% | 0.02% | +4.5% |
Q2 2021 | $765,000 | – | 22,589 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |